Altimmune, INC

Altimmune announced positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder, meeting primary and key secondary endpoints.

Altimmune announced its first quarter 2026 financial results, highlighting a strengthened balance sheet with over $535 million in cash and plans to initiate its PERFORMA Phase 3 MASH trial in the second half of 2026.

Altimmune, Inc. has closed a public offering of common stock and warrants, raising approximately $211.2 million in net proceeds to fund clinical development.

Altimmune shareholders approved an increase in authorized common stock to 400 million shares at the 2026 Annual Meeting.

Altimmune, Inc. announced its fourth quarter and full-year 2025 financial results, highlighted by positive MASH trial data, FDA Breakthrough Therapy Designation, and plans for a Phase 3 MASH trial in 2026.

Altimmune, Inc. announced the date for its 2026 Annual Meeting of Stockholders and updated deadlines for stockholder proposals and director nominations.

Altimmune, Inc. details its first-quarter 2026 financial performance and progress in its late-stage clinical trials for liver disease treatments, including pemvidutide.

Altimmune, a late clinical-stage biopharmaceutical company, reported a reduced net loss in Q3 2025, bolstered its cash position, and announced positive clinical trial updates for its lead drug candidate, pemvidutide, despite facing new legal challenges.

Altimmune, Inc. reported a narrower net loss in Q2 2025, driven by reduced R&D expenses, while its lead MASH drug, pemvidutide, demonstrated significant resolution rates in its Phase 2b trial.

Altimmune, a late clinical-stage biopharmaceutical company, announces its financial results for the first quarter of 2025 and provides an update on its business operations, including progress on its lead program, pemvidutide, and expansion into new indications.

Altimmune's Q3 2024 report highlights progress in its pemvidutide program, including the completion of an End-of-Phase 2 meeting with the FDA and the design of a Phase 3 registrational program for obesity.

Altimmune's Q2 2024 results show increased R&D spending on pemvidutide, a net loss of $49 million for the first six months, and ongoing legal challenges.

Altimmune reports strong Phase 2b MASH results for pemvidutide, secures FDA designations, and advances trials for AUD and ALD, signaling significant pipeline progress.

Altimmune reports its 2024 financial results and provides an update on its clinical programs, highlighting the advancement of pemvidutide to Phase 3 trials for obesity and ongoing Phase 2b trial for MASH.

Altimmune's 10-K filing outlines the company's share structure, voting rights, dividend policies, and regulatory framework, including details on common and preferred stock, warrants, and anti-takeover provisions.

Gregory L Weaver, Chief Financial Officer of Altimmune, Inc., received 1,753 shares of common stock on July 31, 2026.

M Scot Roberts, Chief Scientific Officer of Altimmune, Inc., received 875 shares of common stock on July 31, 2026.

Director Teri Lawver was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Altimmune, Inc. director Catherine A. Sohn received 48,800 stock options as part of the company's standard non-employee director compensation policy.

Altimmune, Inc. director Diane Jorkasky has been granted 48,800 stock options as part of the company's standard non-employee director compensation policy.

Director Klaus Schafer was granted 48,800 stock options in Altimmune, Inc. as part of the company's non-employee director compensation policy.

Altimmune, Inc. will hold its 2026 Annual Meeting to vote on director elections, auditor ratification, executive pay, and proposals to increase authorized common stock and expand its employee stock purchase plan.

Altimmune, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on September 25, 2025, focusing on director elections, auditor ratification, and executive compensation.

Altimmune, Inc. has scheduled its 2024 Annual Meeting of Stockholders for September 26, 2024, to be held virtually, where stockholders will vote on director elections, auditor ratification, executive compensation, and other business matters.

State Street Corporation has reported beneficial ownership of 5.5% of Altimmune Inc.'s common stock as of March 31, 2026.

Viking Global Investors LP has reported a 6.7% beneficial ownership stake in Altimmune, Inc. following a recent underwritten offering.

TCG Crossover and Chen Yu have reported a combined beneficial ownership of 9.8% in Altimmune, Inc. following a recent underwritten offering.

RA Capital Management and its principals have reported a 6.5% beneficial ownership stake in Altimmune, Inc. following a recent equity offering.

Deep Track Capital and David Kroin have reported a 9.99% beneficial ownership stake in Altimmune, Inc. through common stock and warrant holdings.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Altimmune Inc. common stock following an internal realignment.